PepGen Inc. filed a current report on November 10, 2026, disclosing third quarter 2026 financial results and announcing positive Phase 2 FREEDOM2-DM1 data from its 10mg/kg multiple ascending dose cohort.

Key Highlights

  • Q3 2026 results announced: PepGen reported its financial results for the quarter ended September 30, 2026, furnished as Exhibit 99.1.
  • Phase 2 FREEDOM2-DM1 data: The company announced positive results from its Phase 2 FREEDOM2-DM1 trial at the 10mg/kg dose level, according to the filing.
  • "Highest Reported Splicing Correction": The company's press release title describes the 10mg/kg results as demonstrating the "highest reported splicing correction and improvements across multiple functional measures."
  • Investor presentation filed: A presentation titled "FREEDOM2-DM1, 10 mg/kg MAD Cohort Data Update" was filed as Exhibit 99.3 and incorporated by reference for use in investor meetings.
  • Emerging growth company: PepGen is designated as an emerging growth company under applicable securities regulations, as indicated on the filing's cover page.
  • Signed by CFO: The report was signed by Noel Donnelly, Chief Financial Officer, on November 10, 2026.

PepGen Discloses FREEDOM2-DM1 Phase 2 Findings and Quarterly Financial Update

PepGen Inc. (NASDAQ:PEPG), a Delaware-incorporated biopharmaceutical company headquartered at 321 Harrison Avenue, Boston, Massachusetts, filed this current report to communicate two distinct developments simultaneously. The company furnished a press release covering its financial results for the third quarter ended September 30, 2026, and separately announced clinical data from its ongoing FREEDOM2-DM1 program, which is a Phase 2 study evaluating a 10mg/kg dosing regimen.

According to the filing, the Phase 2 FREEDOM2-DM1 press release is titled "PepGen Announces Positive Phase 2 FREEDOM2-DM1 10mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures." The disclosure was furnished under Item 7.01, Regulation FD, meaning the company made it simultaneously available to the public. Splicing correction is a key biological mechanism relevant to certain genetic diseases where the company focuses its research. PepGen also filed an accompanying investor presentation, described in the filing as the "FREEDOM2-DM1, 10 mg/kg MAD Cohort Data Update," under Item 8.01 as a filed exhibit incorporated by reference.

The financial results press release and the clinical data announcement were both issued on November 10, 2026. The filing notes that the furnished items under Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, are not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and are not automatically incorporated by reference into the company's other filings unless expressly stated. The investor presentation in Exhibit 99.3, filed under Item 8.01, is incorporated by reference. The report was authorized and signed by Chief Financial Officer Noel Donnelly.

What Was Disclosed

PepGen Inc. reported its third quarter 2026 financial results and disclosed Phase 2 clinical data from its FREEDOM2-DM1 10mg/kg cohort on November 10, 2026, filing three exhibits including a press release, a clinical data announcement, and an investor presentation.